Full-Time

Senior Director

Finance

Freenome

Freenome

201-500 employees

Blood-based multiomics cancer detection tests

Compensation Overview

$229.9k - $294.8k/yr

+ Equity + Bonus

Daly City, CA, USA

Hybrid

Category
Finance & Banking (2)
,
Required Skills
Machine Learning
Financial Modeling
Requirements
  • Bachelor’s degree in finance, accounting, or a related field.
  • 12+ years of progressive finance experience in corporate finance, financial modeling, analysis, forecasting, and business partnering.
  • 6+ years of experience building, leading, and developing high-performing finance teams.
  • Prior leadership as head of the FP&A function at a publicly traded company.
  • Strategic mindset with proven ability to align financial strategies with business goals.
  • Results-driven and metrics-oriented approach, with a focus on driving growth and proactively mitigating financial risks.
  • Sought as a trusted advisor to the business leveraging superior business partnering skills and business acumen.
  • Proven ability to effectively manage and deliver multiple, large-scale projects while maintaining business and financial service excellence.
  • Consistently monitors the business and markets, adapting where needed to ensure business success.
  • Passion for getting in the trenches, leading by example, and influencing process excellence across the organization.
  • Exceptional executive communication skills, with a proven ability to distill complex data into clear, concise, and impactful insights to facilitate high-velocity, informed decision making.
Responsibilities
  • Accountable for Financial Planning and Analysis, business partnering, and finance operations maintaining clear financial controls and compliance.
  • Develop the financial frameworks for our commercial launches, including revenue forecasting, COGS analysis, and go-to-market spend optimization.
  • Lead the (AOP) annual operating plan process, rolling quarterly forecasts, and long-range strategic planning models, scaled by technology.
  • Build and maintain a detailed financial model to forecast future performance, report budget to actuals.
  • Influence key decisions by delivering high value financial analysis that highlight root causes of variance, trends, and identify actionable opportunities to invest, reduce costs, and mitigate risks.
  • Create actionable KPI dashboards specific to a commercial-stage diagnostic company, such as test volume, ASP, and COGS per test.
  • Increase the speed and efficiency of our FP&A efforts driving the timely delivery, quality, and transparency of information to support business decisions.
  • Proactively partner with the senior leadership team and cross-functional stakeholders to align financial objectives with our business strategy and drive key decision-making.
  • Identify and manage financial risks monitoring market conditions, developing risk mitigation strategies, and implementing relevant programs.
  • Proactive collaboration with leaders within the finance organization to align systems, processes, and initiatives to enable seamless support.
  • Drive the implementation, buildout, and continuous improvement of key financial systems, such as ERP, planning and budgeting systems and business intelligence tools.
  • Champion the application of AI, machine learning, and automation to increase efficiency and enhance predictive accuracy in our models.
  • Lead financial diligence for potential partnerships, acquisitions, or strategic initiatives.
  • Participate in audit committee activities as needed.
Desired Qualifications
  • MBA or CFA preferred.
  • Biotech experience preferred.

Freenome develops non-invasive blood tests for early cancer detection by combining genomics and proteomics to identify cancer signals in blood. The tests are sold to healthcare providers and research institutions and are also used in clinical trials and collaborations. The process involves analyzing a blood sample with proprietary algorithms to assess cancer risk and guide follow-up diagnostics. By integrating multiple data types and pursuing large-scale trials, Freenome aims to make early cancer screening routine and improve patient outcomes, with a focus on expanding colorectal cancer testing.

Company Size

201-500

Company Stage

Late Stage VC

Total Funding

$1.1B

Headquarters

San Francisco, California

Founded

2014

Simplify Jobs

Simplify's Take

What believers are saying

  • SimpleScreen CRC FDA approval expected H2 2026 unlocks $2B+ colorectal cancer screening market.
  • SPAC merger with Perceptive Capital Solutions provides $330M funding for multi-cancer pipeline expansion.
  • Roche $75M investment and $200M+ deal validates technology and accelerates global commercialization.

What critics are saying

  • Exact Sciences exclusive U.S. rights eliminate Freenome's domestic revenue and commercialization control.
  • SPAC merger failure depletes cash reserves after 100-employee layoffs, halting product launches.
  • Guardant Health's Shield test captures 70% market share, undercutting Freenome's multiomics platform.

What makes Freenome unique

  • Multiomics platform analyzes DNA, immune, and metabolic signals for earliest cancer detection.
  • Secured exclusive U.S. colorectal cancer rights deal with Exact Sciences worth up to $775 million.
  • Roche partnership enables kitted decentralized testing and Axelios sequencing technology evaluation internationally.

Help us improve and share your feedback! Did you find this helpful?

Your Connections

People at Freenome who can refer or advise you

Benefits

Competitive market-based salaries

Annual bonus opportunities

Relocation packages

Medical, dental, & vision coverage

401k

Wellness programs

Equity

PTO

Growth & Insights and Company News

Headcount

6 month growth

-1%

1 year growth

0%

2 year growth

-3%
BioPharma Dive
Nov 20th, 2025
Roche inks deal for rights to Freenome cancer tests outside US

Roche inks deal for rights to Freenome cancer tests outside US. Roche is investing $75 million in Freenome as part of the deal, which comes a year after the Swiss company led a $254 million financing round. Dive brief: * Roche has struck a deal to commercialize Freenome's cancer screening technology outside the U.S., the companies said Tuesday. * Freenome will receive a $75 million investment from Roche as part of a deal that could be worth more than $200 million. * The deal positions Freenome, which currently uses Illumina machines, to evaluate Roche's new sequencing device. In a note to clients, Leerink Partners analysts said they see no near- to medium-term impact on Illumina. Dive insight: Nearing pre-market approval of its colorectal cancer blood-based screening test, Freenome has struck deals to support its commercialization in recent months. In August, Exact Sciences agreed to pay Freenome $75 million upfront, plus up to $700 million in milestones, for U.S. rights to current and future versions of the test. Roche's deal covers the marketing of "kitted" tests in areas outside of the U.S. Kitted tests package the software and assay to enable decentralized test processing and analysis, eliminating the need for a singular large processing lab. Freenome has retained rights to centralized testing outside the U.S. Roche, meanwhile, could shell out milestone payments and royalties on ex-U.S. sales. The $75 million equity investment increases Roche's stake in Freenome after leading a $254 million financing round last year. Other Roche investments, such as positions backing Flatiron Health and Foundation Medicine, have resulted in acquisitions. Freenome already uses Roche's Elecsys technology for multiple types of analyses. Under the new deal, Freenome will study the potential for Roche's "sequencing by expansion" technology to enhance its cell-free DNA cancer screening tests. Freenome will also gain access to Roche plasma sample cohorts to support the development of personalized screening tests for multiple types of cancer. Roche unveiled its sequencing technology in February and provided more information at its diagnostics day in May. At that event, Josh Lauer, the company's head of molecular labs, said "speed is something very unique about this platform and something no other short-read sequencer is able to match." Leerink analysts evaluated the threat the technology - which Roche has branded Axelios - poses to Illumina in light of the Freenome agreement. The analysts said the deal "highlights Roche's long-term strategy for Axelios - a clinical box for running NGS kits, similar to with their prior success in IVD kits." Yet it will take a few years of testing and refinement to ready Axelios for clinical sequencing, they added. "We don't expect other oncology Dx companies to jump to try Roche SBX in [the] U.S. or internationally given their new assays are already entrenched and some are FDA approved on [Illumina] sequencers," the analysts said in a note to investors. "Switching costs and reliability needs are high and clinical Dx companies indicate they won't entertain the switch without a clear value proposition."

Freenome
Nov 19th, 2025
Freenome Announces Exclusive Agreement with Roche to Expand Technology Collaboration and Develop and Commercialize Cancer Screening Tests Outside the U.S.

– Partnership focuses on “kitted” tests in ex-U.S. markets, enabling accelerated access through a decentralized model – – Deal potentially […]

finanzen.net
Nov 18th, 2025
Freenome, Roche Partner in $200M Deal

Freenome has partnered with Roche in a deal potentially worth over $200 million to commercialize its cancer screening technology in international markets. The agreement includes a $75 million equity investment from Roche and focuses on developing "kitted" tests for decentralized processing. Freenome will also evaluate Roche's Sequencing by Expansion technology. This collaboration aims to enhance Freenome's multiomic blood-based cancer screening platform and expand its global reach.

PR Newswire
Jun 2nd, 2025
Freenome Announces Jama Publication Of Data From Pivotal Study Of Its Blood-Based Test For Colorectal Cancer

– PREEMPT CRC, the largest prospective study of its kind, met all primary efficacy endpoints and surpassed CMS coverage requirements for sensitivity and specificity in the intended use population –. – FDA premarket approval submission is underway, with completion anticipated mid-2025 –. BRISBANE, Calif., June 2, 2025 /PRNewswire/ -- Freenome, a biotechnology company pioneering an early cancer detection platform, today announced the publication of detailed results from the pivotal PREEMPT CRC study in JAMA.1 The publication presents findings from the largest prospective study of a blood-based screening test for colorectal cancer (CRC), involving 48,995 average-risk adults aged 45 to 85 who underwent a routine colonoscopy following a blood draw

Health Technology Insights
May 21st, 2025
Freenome Appoints Linh H. Le as Chief Financial Officer

Freenome appoints Linh H. Le as chief financial officer.